Products aimed at treating or reducing the appearance of cellulite are expected to see increased demand as obesity rates continue to climb worldwide.
London-based Triton Market Research released a report projecting a 9.48% surge in revenue for the cellulite treatment market in the next seven years. This means that the market can expect to be worth around $4.5 billion by 2030, with some dampening factors, including the high costs and adverse side effects associated with anti-cellulite treatments.
Cellulite is a condition in which stored fat pushes against the connective tissue beneath the skin, causing the surface of the skin to appear lumpy and dimpled. It disproportionately affects women, with somewhere between 80% and 90% having it to some extent compared to just 10% of men.
While harmless, some might consider cellulite unsightly and seek to minimize its appearance by applying creams or undergoing cosmetic procedures — many of which cause skin discomfort and yield marginal or temporary results. Although one’s propensity for cellulite might depend on age, skin thickness, and genetics, how severe it is ultimately tends to come down to how much body fat a person has.
For instance, severe cellulite, characterized by deep depressions that make the skin resemble an orange peel, is believed to be brought on by several lifestyle factors, including obesity, lack of exercise, hormonal imbalances, and poor diet.
As recently reported by The Dallas Express, the number of people considered to be clinically obese has reached over 1 billion worldwide. With obesity being linked to a multitude of negative health outcomes — ranging from heart disease to dementia — this increase in prevalence has sounded alarm bells among public health authorities, such as the World Health Organization.
Yet there are effective anti-obesity therapeutical options available nowadays, such as the blockbuster GLP-1 class weight loss drugs like Ozempic and Wegovy. However, many more might still be on the horizon as researchers dive deeper into the body’s metabolic functioning. For instance, Eli Lilly’s bimagrumab has recently been shown to help users shed fat while maintaining muscle mass in clinical trials.
